Astellas (4503) - PROSPER Data Revives Value Story
For a drug that was targeted to hit US$6~8bil in sales, last year’s US$2.3bil revenue figure for Xtandi was decidedly below par. With the start of...
158 Views
Update on Astellas (4503) As It Gets Orphan Drug Status for Gilteritinib
News that gilteritinib has received orphan drug status for acute myeloid leukaemia (AML) would be rather more exciting for Astellas (4503 JP) but...
197 Views
Takeda - Brigantinib Gets FDA Approval
Earlier this year, Takeda Pharmaceutical Co Ltd (4502 JP) spent US$4bil on Ariad Pharmaceuticals Inc (ARIA US), thereby acquiring a company with a...
287 Views
Most / Least Popular Sectors in Japan over Last 2 Weeks....
Over the last 2 week we saw a dip in the number of Analyst Upgrade/Downgrades, most likely due to the fact Earnings is right around the corner....
471 Views
Astellas (4503) Implications of Ogeda Acquisition
At first glance, Astellas Pharma's decision to buy closely-held Belgian biotech firm Ogeda for ¥90bil (US$800mil) is essentially a licensing deal...
350 Views